Preliminary observations on the administration of a glucagon-like peptide-1 receptor agonist on body weight and select carbohydrate endpoints in persons with spinal cord injury: A controlled case series.

Cirnigliaro CM, La Fountaine MF, Sauer SJ, Cross GT, Kirshblum SC, Bauman WA

The journal of spinal cord medicine9 May 2023Cited by 9 (Europe PMC)

PMID37158751PMCIDPMC11218576DOI10.1080/10790268.2023.2207064PepBankPUB-37158751

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanCase report or seriesEfficacy outcome
In 3 adults with spinal cord injury and obesity, total body weight fell on average by 6 after 26 weeks of semaglutide.
In plain wordsIn 3 people with spinal cord injury and obesity, body weight went down after 26 weeks of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseTotal body weight change
Study
n = 3
Comparator
No treatment (control)
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Total body weight change
−6 unit not stated
semaglutide
Source sentences
Summary
In 3 participants, after 26 weeks of semaglutide administration, TBW, FTM, TBF%, and VAT_vol decreased, on average, by 6, 4.4 kg, 1.7%, and 674 cm³, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Five individuals with chronic SCI meeting criteria for obesity and abnormal carbohydrate metabolism.
Summary · context
Administration of semaglutide (subcutaneously once per week) versus no treatment (control) for 26 weeks.
Report a problemFND-3715875101
02HumanCase report or seriesEfficacy outcome
In 3 adults with spinal cord injury and obesity, fat tissue mass fell on average by 4.4 kg after 26 weeks of semaglutide.
In plain wordsIn 3 people with spinal cord injury and obesity, body fat mass went down after 26 weeks of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseFat tissue mass change
Study
n = 3
Comparator
No treatment (control)
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Fat tissue mass change
−4.4 kg
semaglutide
Source sentences
Summary
In 3 participants, after 26 weeks of semaglutide administration, TBW, FTM, TBF%, and VAT_vol decreased, on average, by 6, 4.4 kg, 1.7%, and 674 cm³, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Five individuals with chronic SCI meeting criteria for obesity and abnormal carbohydrate metabolism.
Summary · context
Administration of semaglutide (subcutaneously once per week) versus no treatment (control) for 26 weeks.
Report a problemFND-3715875102
03HumanCase report or seriesEfficacy outcome
In 3 adults with spinal cord injury and obesity, total body fat percent fell on average by 1.7% after 26 weeks of semaglutide.
In plain wordsIn 3 people with spinal cord injury and obesity, body fat percentage went down after 26 weeks of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseTotal body fat percent change
Study
n = 3
Comparator
No treatment (control)
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Total body fat percent change
−1.7%
semaglutide
Source sentences
Summary
In 3 participants, after 26 weeks of semaglutide administration, TBW, FTM, TBF%, and VAT_vol decreased, on average, by 6, 4.4 kg, 1.7%, and 674 cm³, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Five individuals with chronic SCI meeting criteria for obesity and abnormal carbohydrate metabolism.
Summary · context
Administration of semaglutide (subcutaneously once per week) versus no treatment (control) for 26 weeks.
Report a problemFND-3715875103
04HumanCase report or seriesEfficacy outcome
In 3 adults with spinal cord injury and obesity, visceral adipose tissue volume fell on average by 674 cm3 after 26 weeks of semaglutide.
In plain wordsIn 3 people with spinal cord injury and obesity, belly fat volume went down after 26 weeks of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseVisceral adipose tissue volume change
Study
n = 3
Comparator
No treatment (control)
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Visceral adipose tissue volume change
−674 cm3
semaglutide
Source sentences
Summary
In 3 participants, after 26 weeks of semaglutide administration, TBW, FTM, TBF%, and VAT_vol decreased, on average, by 6, 4.4 kg, 1.7%, and 674 cm³, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Five individuals with chronic SCI meeting criteria for obesity and abnormal carbohydrate metabolism.
Summary · context
Administration of semaglutide (subcutaneously once per week) versus no treatment (control) for 26 weeks.
Report a problemFND-3715875104
05HumanCase report or seriesEfficacy outcome
In 3 adults with spinal cord injury and obesity, fasting plasma glucose fell by 17 mg/dl after 26 weeks of semaglutide.
In plain wordsIn 3 people with spinal cord injury and obesity, fasting blood sugar went down after 26 weeks of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseFasting plasma glucose change
Study
n = 3
Comparator
No treatment (control)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 26 weeksAs given in this study (human).
Measurements
Fasting plasma glucose change
−17 mg/dl
semaglutide
Source sentences
Summary
In addition, values for FPG and HbA1c decreased by 17 mg/dl and 0.2%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Five individuals with chronic SCI meeting criteria for obesity and abnormal carbohydrate metabolism.
Summary · context
Administration of semaglutide (subcutaneously once per week) versus no treatment (control) for 26 weeks.
Report a problemFND-3715875105
06HumanCase report or seriesEfficacy outcome
In 3 adults with spinal cord injury and obesity, HbA1c fell by 0.2% after 26 weeks of semaglutide.
In plain wordsIn 3 people with spinal cord injury and obesity, HbA1c, a long-term blood sugar marker, went down slightly after 26 weeks of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change
Study
n = 3
Comparator
No treatment (control)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 26 weeksAs given in this study (human).
Measurements
HbA1c change
−0.2%
semaglutide
Source sentences
Summary
In addition, values for FPG and HbA1c decreased by 17 mg/dl and 0.2%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Five individuals with chronic SCI meeting criteria for obesity and abnormal carbohydrate metabolism.
Summary · context
Administration of semaglutide (subcutaneously once per week) versus no treatment (control) for 26 weeks.
Report a problemFND-3715875106

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT03292315

Once Weekly GLP-1 in Persons With Spinal Cord Injury

James J. Peters Veterans Affairs Medical Centern = 516 Oct 2018 to 1 Mar 2023

Spinal Cord Injuries · Insulin Resistance · Pre Diabetes · Obesity

Trial page ClinicalTrials.govUpdated 14 Mar 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.